Provides consumers with digital clinical care, prescription and nonprescription treatments, and laboratory testing, and sells nonprescription wellness products to retailers.
10-K for FY2025, filed Feb 23, 2026Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, “Hims & Hers”, the “Company”, “we”, “us” or “our”) has…View ↗
We are a consumer-first health and wellness platform focused on providing access to modern personalized health and wellness solutions to…View ↗
We also offer over-the-counter drug and device products and cosmetics and supplement products, which are primarily focused on general…View ↗
In addition to prescription medications and over-the-counter products, we offer access to laboratory testing services to measure a broad…View ↗
Individuals buy health and wellness products and services online; most online sales are subscriptions billed on the customer’s selected shipment cadence, while some are one-time purchases. Retailers buy nonprescription products through wholesale agreements.
10-K for FY2025, filed Feb 23, 2026“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes…View ↗
For subscription plans, in addition to a 30-day cadence or treatment term, we offer customers the ability to select from a range of…View ↗
“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also…View ↗
$2.3B
10-K for FY2025, filed Feb 23, 2026
$2.3B ↗
Most customers are individuals buying through the company’s websites or apps. Retailers buy nonprescription products under wholesale agreements, and sales also go through third-party platforms.
10-K for FY2025, filed Feb 23, 2026
Yes. It kept 5 cents of every revenue dollar as net income in FY2025 and turned 2 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$33MView ↗
8-K, filed Nov 9, 2026
Tightens full year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and reduces Adjusted EBITDA guidance to a range of…View ↗
8-K, filed Jun 2, 2026
SAN FRANCISCO, June 2, 2026 – Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as…View ↗
Growing. Revenue grew 8.6x in 4 years, from $271.9M in FY2021 to $2.3B in FY2025, about 71% a year.
Specialty expansion
The older report listed testosterone, menopause and weight management as future opportunities; the latest says the company offers hormone and weight-loss care and launched testosterone, menopause and perimenopause support.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 23, 2026We are pursuing a roadmap of rapid category expansion into new conditions that can be treated safely via telehealth, require ongoing and…View ↗
International expansion
The older report described expansion in the United Kingdom and further international opportunities as a goal; the latest says the company has established operations in the United Kingdom, parts of the European Union and Canada.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 23, 2026Our strong brand and digital-first, cloud-based business model has driven rapid adoption in the U.S. Additionally, our model has been…View ↗
We view international expansion as a core pillar of our long-term growth strategy. Our digital-first, cloud-based platform and trusted…View ↗
Loading...